Medicxi

We are proud to announce the acquisition of @centessa by @EliLillyandCo for a total of $7.8B Congratulations to current CEO Mario Accardi, former CEO Saurabh Saha and the entire Centessa Team investors.centessa.com/news-releases/…

We are proud to unveil our latest fund Medicxi V Through this €500M fund we will continue our dedicated support for innovative biotech companies and world-class drug hunters with clear product visions to transform patient care medicxi.com/news/medicxi-a…

This marks Servier’s first asset acquisition in neurology, and following a recent positive Ph1 study under the stewardship of Rob Ring and Kaerus’ team, Servier plans to commence Ph2 development in 2026

Kaerus is an asset-centric company founded by Medicxi, to develop small molecules that target the core pathology in Fragile X Syndrome by restoring aberrant neuronal potassium channel function in these patients

Delighted to announce that KER-0193, a potential treatment for Fragile X syndrome being developed by Kaerus Bioscience, has been acquired by @Servier for up to $450M Congratulations to Rob Ring and the entire Kaerus team for this fantastic outcome! kaerusbio.com/copy-of-2025-5…

Partnering with @sanofi will help accelerate clinical development of VXB-241 and next generation products This is a fantastic outcome for the Vicebio platform and for patients suffering these viral respiratory infections

Vicebio was created by @medicxi to develop next-generation vaccines for respiratory viruses, utilising its proprietary Molecular Clamp technology The lead asset, VXB-241, is a bivalent vaccine targeting RSV and hMPV, currently in Phase 1 clinical development

Thrilled to announce that @medicxi portfolio company Vicebio has entered into an exclusive agreement to be acquired by @sanofi for $1.6B, including an upfront payment of $1.15B 🚀🚀 prnewswire.com/news-releases/…

Rhinovirus infections account for >45% of COPD exacerbations and are associated with poorer outcomes for patients with COPD Vapendavir has potent activity against 97% of rhinoviruses, and could help prevent the devastating consequences of rhinovirus-mediated COPD exacerbations

In this placebo-controlled study, treatment with vapendavir was well tolerated, led to faster reduction in viral load and a shorter overall course of illness with fewer adverse and severe adverse respiratory events versus placebo

Congratulations to the Altesa Biosciences team on reporting positive Phase 2 data for vapendavir in a Rhinovirus challenge study in patients with COPD prnewswire.com/news-releases/…

Medicxi is joined by other new investors OrbiMed, HBM Healthcare Investments and Sanofi Ventures, with participation of current insiders Funding will support completion of Phase 2 development, with a clear path towards Phase 3 and market authorization

Curevo is developing Amezosvatein, to address critical unmet needs in shingles vaccination In Phase 2, Amezosvatein demonstrated competitive efficacy and potential for superior tolerability versus Shingrix, thanks to Curevo’s proprietary adjuvant technology

Excited to announce that Medicxi has led Curevo Vaccine’s $110M Series B financing As part of this financing, Giovanni Mariggi will join the board of directors, alongside vaccine industry leaders Moncef Slaoui and Tal Zaks endpts.com/curevo-gets-11…

Kaerus will advance KER-0193 into Phase 2 proof-of-concept study later this year, moving one step closer to providing a safe and efficacious therapy to patients with FXS

KER-0193 was safe and well tolerated in 56 healthy volunteers, with positive pharmacodynamic effects confirmed in translationally relevant parameters by pharmaco-EEG

Congratulations to Kaerus Bioscience for successfully completing Phase 1 development for KER-0193, a novel BK channel modulator for Fragile X syndrome (FXS) kaerusbio.com/phase1trial

This marks Alys' first clinical study following its $100M seed financing from @medicxi , with multiple proof-of-concept readouts expected across multiple indications in immune-dermatology by 2027

ALY-101 is the first clinical candidate from Alys' collaboration with the RNA Institute at UMass Chan Medical School, pioneering RNA-based therapies to target the root causes of immune-mediated skin diseases

🚀 Congratulations to Alys Pharmaceuticals on advancing its first intradermally administered siRNA for immune-dermatology into the clinic! The Phase 2a will evaluate the safety & efficacy of ALY-101, a JAK1-targeted siRNA in patients with alopecia areata alyspharma.com/alys-pharmaceu…